SC 13G/A: YS Biopharma Co., Ltd.
Ticker: LSBWF · Form: SC 13G/A · Filed: Feb 16, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Ys Biopharma CO., LTD. (LSBWF) |
| Form Type | SC 13G/A |
| Filed Date | Feb 16, 2024 |
| Risk Level | low |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.00002 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by YS Biopharma Co., Ltd..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G/A filing submitted by Ys Biopharma CO., LTD. (ticker: LSBWF) to the SEC on Feb 16, 2024.
What is the risk level of this SC 13G/A filing?
This filing has been assessed as low risk.
What are the key financial figures in this filing?
Key dollar amounts include: $0.00002 (Issuer) Ordinary Shares, par value US$0.00002 per share (Title of Class of Securiti).
How long is this filing?
Ys Biopharma CO., LTD.'s SC 13G/A filing is 8 pages with approximately 2,519 words. Estimated reading time is 10 minutes.
Where can I view the full SC 13G/A filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 2,519 words · 10 min read · ~8 pages · Grade level 9.4 · Accepted 2024-02-16 16:14:23
Key Financial Figures
- $0.00002 — Issuer) Ordinary Shares, par value US$0.00002 per share (Title of Class of Securiti
Filing Documents
- tm246551d1_sc13ga.htm (SC 13G/A) — 161KB
- tm246551d1_ex99-a.htm (EX-99.A) — 22KB
- 0001104659-24-024912.txt ( ) — 184KB
OWNERSHIP
ITEM 4. OWNERSHIP. The following paragraph is added as the ultimate paragraph of Item 4 of the Schedule 13G: On February 16, 2024, the holders of 62,132,308 shares out of 93,058,197 total issued and outstanding shares of the Issuer, or 66.8%, casted votes at the EGM. The resolutions passed by the shareholders of the Issuer at the EGM are as follows: (a) 55,123,743 shares out of 62,132,308, or 88.7% of the votes cast in person or by proxy, voted in favor of removing the Issuer’s entire board of directors from office; (b) 55,123,743 shares out of 62,132,308, or 88.7% of the votes cast in person or by proxy, voted in favor of electing the seven director nominees; On February 16, 2024, the board of directors of the Issuer casted votes at a meeting of the board of directors (the “ Board Meeting ”). The resolutions passed by [unanimous vote of] the board of directors of the Issuer at the Board Meeting are as follows: (a) the appointment of Mr. Yi ZHANG as the Chairperson of the board with immediate effect; (b) the removal of each of Hui SHAO, Bo TAN, Ajit SHETTY, Viren T. MEHTA, Shaojing TONG and Rachel YU (collectively, the “ Removed Directors ”) from all of the relevant committees of the board of the Issuer including the audit committee, the compensation committee and the nominating and corporate governance committee and from the relevant board and committee (if any) of each subsidiary of the Issuer with immediate effect; (c) the appointment of each of Jing Xian LI, Chi Keung (Peter) LUI and Yun (Monica) ZHANG as a member of the audit committee and Chi Keung (Peter) LUI as the chairperson of the audit committee with immediate effect; (d) the appointment of each of Yun (Monica) ZHANG, Jing Xian LI and Nan ZHANG as a member of the compensation committee and Yun (Monica) ZHANG as the chairperson of the compensation committee with immediate effect; (e) the appointment of each of Yi ZHANG, Yun (Monica) ZHANG and Jing Xian LI as